Intensive chemotherapy for patients newly diagnosed with acute myeloid leukemia (AML) often achieves high remission rates, although these remissions are often only temporary. Consolidation therapy with azacitidine (AZA) extends post-remission survival and disease-free intervals.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
